NasdaqGM - Delayed Quote USD
Protara Therapeutics, Inc. (TARA)
3.2400
-0.1300
(-3.86%)
At close: May 9 at 4:00:00 PM EDT
3.4200
+0.18
+(5.56%)
After hours: May 9 at 7:38:32 PM EDT
Key Executives
Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Jesse Shefferman | Co-founder, CEO, President & Director | 1.14M | -- | 1972 |
| Dr. Jacqueline Zummo M.B.A., M.P.H., Ph.D. | Co-Founder & Chief Scientific Operations Officer | 962.03k | -- | 1981 |
| Mr. Patrick Fabbio M.B.A. | Chief Financial Officer | 782.41k | -- | 1968 |
| Ms. Hannah Fry | VP, Principal Accounting Officer & Controller | -- | -- | 1991 |
| Ms. Justine O'Malley | Senior Vice President of Investor Relations & Corporate Affairs | -- | -- | -- |
| Ms. Mary J. Grendell J.D. | General Counsel & Corporate Secretary | -- | -- | -- |
| Dr. Shane Williams Ph.D. | Chief People Officer | -- | -- | -- |
| Dr. Leonardo Viana Nicacio M.D. | Chief Medical Officer | -- | -- | 1978 |
Protara Therapeutics, Inc.
345 Park Avenue South
3rd Floor
New York, NY 10010
United States
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 28
Description
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
Corporate Governance
Protara Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
August 4, 2025 at 12:30 PM UTC - August 8, 2025 at 12:30 PM UTC
Protara Therapeutics, Inc. Earnings Date
Recent Events
Related Tickers
LRMR Larimar Therapeutics, Inc.
2.1200
-5.36%
CGEM Cullinan Therapeutics, Inc.
7.54
-2.96%
NUVL Nuvalent, Inc.
69.85
-2.44%
VTYX Ventyx Biosciences, Inc.
1.2400
+5.98%
CGON CG Oncology, Inc.
23.74
-1.62%
INZY Inozyme Pharma, Inc.
1.1500
-7.26%
DSGN Design Therapeutics, Inc.
3.5000
-0.57%
URGN UroGen Pharma Ltd.
10.38
-2.72%
GLUE Monte Rosa Therapeutics, Inc.
4.0900
-3.08%
VYNE VYNE Therapeutics Inc.
1.3000
0.00%